The U.S. Food and Drug Administration approved Novo Nordisk’s higher‑dose Wegovy, a semaglutide formulation of 7.2 mg, on March 19 2026. The approval follows the STEP UP phase 3 trial, which demonstrated a mean weight loss of 20.7 % in adults with obesity and 14.1 % in those with type 2 diabetes.
The approval was granted under the FDA’s Commissioner's National Priority Voucher (CNPV) pilot program, a fast‑track pathway that underscores the public‑health importance of obesity treatment and signals the agency’s commitment to advancing therapies that address critical health priorities.
Novo Nordisk plans to launch the new formulation in the United States in April 2026, expanding its obesity‑treatment lineup. The higher‑dose option offers a more potent treatment for patients who have tolerated the standard 2.4 mg dose, thereby helping the company retain patients within its portfolio and counter competition from Eli Lilly’s tirzepatide and other emerging GLP‑1 therapies.
Management highlighted the significance of the approval, stating, "Since its launch in 2021, Wegovy® has transformed the lives of many people living with obesity and helped them achieve meaningful weight loss and important cardiometabolic benefits, including an unprecedented reduction in cardiovascular risk." The company added, "Earlier this year, we launched the Wegovy® pill, and with the accelerated approval of Wegovy® HD, we are introducing a new offering for our injectable semaglutide that provides even greater weight loss of approximately 21 %."
The higher‑dose approval expands Novo Nordisk’s obesity portfolio and positions the company to capture a larger share of the rapidly growing market. The approval also precedes the patent expiry of semaglutide in India and China, where biosimilar competition could emerge, adding a strategic consideration for the company’s global growth strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.